JUV-161 was discovered using Juvena's proprietary JuvNET platform, an AI and stem cell secretome-based drug discovery and development platform "JUV-161 is a natural, endocrine protein therapy that ...
Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses getting JUV-161 into Phase I trials this year. In this Pharmaceutical Executive video interview, Hanadie Yousef, PhD, ...
Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses Juvena’s "pipeline in a product" JUV-161 and plans to broaden into other disease indications. In this Pharmaceutical Executive ...
REDWOOD CITY, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. ("Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results